Biogen Crushes Earnings Estimates. As Old Blockbusters Fade, New Bets Pick Up the Slack. — Barrons.com

What happened

Biogen reported third-quarter revenue up 11% to $2.8 billion, beating forecasts of $2.6 billion, and adjusted earnings of $2.62 a share versus $1.99 expected. The company raised the lower end of its full-year adjusted earnings guidance to $12.20 to $13 a share.

Confirmed

Global impact / market context

New growth areas are offsetting decline in the older multiple sclerosis business, whose revenue fell 13% to $919 million amid generic and biosimilar competition. That shift matters because it shows whether Biogen can replace fading sales with new products and acquisitions before the older franchise shrinks further.

Analyst inference

The results suggest Biogen's growth portfolio and the Apellis acquisition are adding revenue while its legacy treatments lose market share. For investors, the key question is whether this replacement rate holds, since the multiple sclerosis unit still supplies a large share of total revenue.

Analyst inference

What to watch

1. Watch whether revenue from the multiple sclerosis portfolio stays below $1 billion for a fourth straight quarter, after falling 13% to $919 million. Confirmed
2. Track rare-disease revenue, which jumped 27% to $676 million, with more than half from Spinraza, to see if it keeps offsetting the MS decline. Confirmed
3. Watch whether the Apellis acquisition and newer products sustain growth, since slower replacement of fading legacy sales could pressure future revenue and earnings. Analyst inference

Evidence

• Original source link unavailable